![Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) - eClinicalMedicine Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b72bb60f-cd80-4b43-86cb-3042ca7acfb9/gr1_lrg.jpg)
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) - eClinicalMedicine
![Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3177a3f3-5388-4df0-b83b-b35e6ecf71a3/gr1_lrg.gif)
Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology
![Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay: Molecular Therapy - Nucleic Acids Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/5fa811ab-afce-4aab-9e4c-35fdb172c24b/fx1_lrg.jpg)
Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay: Molecular Therapy - Nucleic Acids
![Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs41231-019-0050-7/MediaObjects/41231_2019_50_Fig1_HTML.png)
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text
![Machine learning identifies candidates for drug repurposing in Alzheimer's disease | Nature Communications Machine learning identifies candidates for drug repurposing in Alzheimer's disease | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-21330-0/MediaObjects/41467_2021_21330_Fig1_HTML.png)
Machine learning identifies candidates for drug repurposing in Alzheimer's disease | Nature Communications
![Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay: Molecular Therapy - Nucleic Acids Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/asset/04ed077e-7b6b-40f7-8fb8-ecb6b463f4aa/fx1.jpg)